Clinical Analysis Of Embosphere Microspheres In The Treatment Of Hepatocellular Carcinoma With TACE

Objective To compare the clinical efficacy of Embospher microspheres combined with iodized oil emulsion and conventional iodized oil emulsion in the treatment of liver cancer with TACE.Methods The clinical data of patients with primary carcinoma of liver(PCL)underwent transcatheter arterial chemoembolization(TACE)from October 2015 to October 2016,with an average follow-up of 6 months from the first line of TACE.According to whether or not the use of Embospher microspheres in TACE,divided into microspheres(EM-TACE)and conventional group(c-TACE).According to the inclusion criteria,the two groups of patients in the age,gender,HBs Ag,Barcelona clinical stage(BCLC),tumor size,number,blood supply and border conditions and other aspects of the same.The changes of liver function and alpha-fetoprotein(AFP)were compared between the two groups after TACE treatment,and the local control of tumor was observed 1-7days after TACE and 4-6 weeks after the last treatment.And to evaluate the local control of liver cancer at 4-6 weeks after the first and last TACE according to the m RECIST criteria.Results A total of 85 patients met the inclusion criteria.40 patients in the EM-TACE group and 45 patients with the c-TACE group.All patients underwent 2-4 times of TACE during the follow-up.During the first TACE treatment,79 patients underwent superselective transcatheter arterial chemoembolization.The success rate technically was93%(79/85).In the multiple treatment process,no case of liver failure,liver abscess,acute cholecystitis and other serious complications.During the follow-up period,the patients in the EM-TACE group received 132 treatments,3.3 times per patient,62 cases of postoperative fever,48 cases of abdominal pain,37 cases of nausea or vomiting;but in c-TACE group there were 151 treatments with3.4 times per patient,and Postoperative adverse reactions 71 cases,52 cases,43 cases.The two groups were no significant differences.The levels of liver function,alanine aminotransferase(ALT),aspartate aminotransferase(AST),albumin(ALB),serum total bilirubin(STB),and conjugated bile(CB)increased or decreased in different degrees,but there was no significant differences between the two groups.There was no significant differences in liver function at 4 to 6 weeks after TACE.At the first TACE and the last TACE 4-6 weeks after surgery,AFP were significantly decreased in both groups,and EM-TACE group decreased more significantly.After the first TACE 4-6 weeks,to review the upper abdominal enhanced CT or MRI,according to m RECIST standard to evaluate tumor control.The patients in EM-TACE group,CR,PR,SD and PD were respectively counted in 2 cases,20 cases,16 cases,2cases,the overall response rate(CR+PR)was 55.0%,the clinical benefit rate(CR+PR+PD)was 95.0%;c-TACE group,respectively,0 cases,15 cases,26 cases,4 cases,the response rate was 33.33 %,The benefit rate was 91.11%,and the two groups were statistically significant(P<0.05).At 1 month after the last TACE,in EM-TACE group,the counts of CR,PR,SD,PD patients were 2 cases,2 cases,11 cases,2 cases,and(CR+PR)was48%,(CR+PR+SD)was 92%;but in c-TACE group,the data are respectively 0 cases,7cases,14 cases,4 cases,28% and 84%,and they were significant difference(P<0.05).Conclusion Embospher microspheres combined with iodized oil chemotherapy emulsion treatment of medium-term liver cancer,patient tolerance can be safe and feasible,and conventional treatment no significant difference;tumor local control rate is better than conventional iodized oil chemotherapy embolism.It is conducive to precise embolism with the use of microcatheter ultraselective technology,also can reduce the normal liver injury.The prognosis of liver cancer are related to BCLC clinical stage,tumor size,number,Child classification and other factors and so on,but the regular review of patients and follow-up is also an important factor affecting the prognosis.